Hereditary Cancer Syndromes > PALB2
CANCER
GENETIC CANCER RISK
Female Breast
High Risk
Male Breast
Elevated Risk
Ovarian
Elevated Risk
Pancreatic
Elevated Risk
CANCER TYPE
AGE RANGE
CANCER RISK
RISK FOR GENERAL POPULATION
Female Breast
To age 50
17%
2.1%
To age 80
53%
10.7%
Second primary within 10 years of first breast cancer diagnosis
5%
3.5%
Pancreatic
To age 80
2%-3%
1.1%
Ovarian
To age 80
5%
0.9%
Male Breast
To age 80
1%
0.1%
CANCER TYPE
PROCEDURE
AGE TO BEGIN
FREQUENCY
Female Breast
Breast awareness - Women should be familiar with their breasts and promptly report changes to their healthcare provider. Periodic, consistent breast self-examination (BSE) may facilitate breast awareness.
Individualized
NA
Clinical encounter, including clinical breast exam, ongoing risk assessment and risk-reduction counseling
When genetic risk is identified, but not before age 21
Every 6 to 12 months
Mammography and breast MRI with contrast
Age 30, or modified to a younger age based on family history
Annually
Consider risk-reducing mastectomy.
Individualized
NA
Consider additional risk-reduction strategies.
Individualized
NA
Pancreatic
For patients with a family history of pancreatic cancer, consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in screening for pancreatic cancer, preferably within research protocols.
Age 50, or 10 years younger than the earliest age of pancreatic cancer diagnosis in the family
Annually
Provide education about ways to reduce pancreatic cancer risk, such as not smoking and losing weight.
Individualized
Individualized
Ovarian
Consider bilateral salpingo-oophorectomy (BSO).
After 45 years
NA
Male Breast
Currently there are no specific medical management guidelines for breast cancer risk in mutation carriers. However, the increase in risk warrants consideration of options for male breast cancer screening, such as patient breast awareness education and clinical breast examinations.
Individualized
NA
For Patients With A Cancer Diagnosis
For patients with a gene mutation and a diagnosis of cancer, targeted therapies may be available as a treatment option for certain tumor types (e.g., platinum chemotherapy, PARP-inhibitors)
NA
NA
